ClinicalTrials.gg
RecruitingNCT07480915PROFILE-HFUpdated Oct 6, 2026

Risk Stratification of MACE in Heart Failure Patients Who Undergoing CABG

An observational study in Heart Failure, CAD - Coronary Artery Disease and CABG, sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences. Recruiting at 1 site in Russia. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
160
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Heart Failure with a site in Russia — 9 open to participants now, 10 under way, none of them phase 3. Heart Failure · Russia.

Planned enrollment
7th of 10
160 · median 250
Started
2026
with 2 others
Observational
10 of 25
6 open now
Registered
23rd of 25
by date
Lead sponsor
4 of 25
Tomsk National Research Medical Center of the Russian Academy of Sciences

Among the 25 studies in Heart Failure with a site in Russia, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2026, is one of 10 observational ones, and was the 23rd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

9 of the 25 studies in Heart Failure with a site in Russia are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Heart Failure with a site in Russia, or all of them as a file.
02

Study summary

PROFILE-HF is a multicenter, observational, prospective study of the clinical course and outcomes of chronic heart failure (HF) and coronary artery disease (CAD) in patients undergoing coronary artery bypass grafting (CABG).

The objective of the study is to develop a method for assessing the risk of adverse cardiovascular events in patients with CAD and HF who have undergone CABG, based on preoperative GDF-15 concentrations.

The study will have a 12-month follow-up period; one in-person visit is planned at the end of the follow-up period. If it is not possible to visit a doctor in person, information will be collected through telephone contact with the patient or his relative or person caring for the patient.

Read the detailed description

PROFILE-HF is a multicenter, observational, prospective study of the clinical course and outcomes of chronic heart failure (HF) and coronary artery disease (CAD) in patients undergoing coronary artery bypass grafting (CABG).

The objective of the study is to develop a method for assessing the risk of adverse cardiovascular events in patients with CAD and HF who have undergone CABG, based on preoperative GDF-15 concentrations.

The study will include patients with a documented diagnosis of CHF and CAD who are recommended for coronary artery bypass grafting by the cardiac team.

The study will collect and record patient examination and treatment data, which will be conducted in accordance with established standards of care for patients with CAD and will not be part of the study.

The study will also analyze GDF-15. At each study center, upon patient enrollment, after signing informed consent, blood will be collected from the cubital vein in the morning before CABG. The blood will be collected in a vacuum tube containing 8 ml of clot activator (red-topped vacutainer) containing clot activator. Further preparation of the blood samples for analysis will include centrifugation for 10 minutes at 2,500 rpm, separation of the serum using a pipette into three 500 μg Eppendorf tubes, and freezing at -20°C. Serum samples will be transported by a specialized cold chain company. Analysis will be performed after a single thaw of the serum/plasma in the laboratory of the Cardiology Research Institute of Tomsk National Research Medical Center.

The study will have a 12-month follow-up period; one in-person visit is planned at the end of the follow-up period. If it is not possible to visit a doctor in person, information will be collected through telephone contact with the patient or his relative or person caring for the patient.

03

Conditions studied

  • Heart Failure
  • CAD - Coronary Artery Disease
  • CABG

Keywords

  • Heart Failure
  • Coronary Artery Disease
  • CABG
  • Coronary Artery Bypass Grafting
  • GDF-15
  • Growth differentiation factor - 15
  • Prognosis
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

At each study center, patients with CHF and ischemic heart disease will be assessed for inclusion and exclusion criteria when deciding on the need for CABG and whether the patient consents to the procedure. The principal investigator is expected to ensure that all patients meeting the inclusion and exclusion criteria are consistently enrolled in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Heart Failure
  • Planned coronary artery bypass grafting

Exclusion criteria

Exclusion Criteria:

  • Myocardial infarction
  • Stroke
  • Presence of implanted devices;
  • Need for additional cardiac surgery other than coronary artery bypass grafting (valve repair, aneurysm);
  • Severe renal dysfunction ( \<30 ml/min/1.73 m2);
  • Severe comorbidities: active cancer; infiltrative cardiac diseases (sarcoidosis, amyloidosis, storage diseases); diseases; acute infectious diseases and exacerbations of chronic somatic diseases.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Time to first adverse cardiovascular event (months)

    Time to first adverse cardiovascular event, including cardiovascular (CV) death or nonfatal myocardial infarction (MI) and/or nonfatal stroke and/or unplanned revascularization and/or heart failure (HF) hospitalization and/or worsening of heart failure (worsening by at least one NYHA class requiring increased intensity of diuretic therapy).

    Time frame: From enrollment to the end of treatment at 12 months

Secondary outcomes

  1. Deaths from cardiovascular causes (percentage)

    Frequency of deaths from cardiovascular causes (percentage)

    Time frame: From enrollment to the end of treatment at 12 months

  2. All-cause mortality

    All-cause mortality rate (percentage)

    Time frame: From enrollment to the end of treatment at 12 months

  3. HF hospitalization (percentage)

    Frequency of cases of HF hospitalization (percentage)

    Time frame: From enrollment to the end of treatment at 12 months

  4. Acute ischemic events (percentage)

    The incidence of acute ischemic events requiring unplanned revascularization (percentage)

    Time frame: From enrollment to the end of treatment at 12 months

  5. Secondary composite endpoint (percentage)

    The incidence of a secondary composite endpoint including cardiovascular (CV) death or nonfatal myocardial infarction (MI) and/or nonfatal stroke and/or unplanned revascularization and/or and HF hospitalization (percentage).

    Time frame: From enrollment to the end of treatment at 12 months

07

Study locations

1 of 1 sites recruiting
  • Cardiology Research Institute, Tomsk National Research Medical Center Russian Academy of Sciences
    Tomsk, Tomsk Oblast 634050, Russia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 12 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 18, 2026
StartActual
Mar 4, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07480915
Lead sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
Responsible party
Elena A. Kuzheleva (Researcher, Tomsk National Research Medical Center of the Russian Academy of Sciences) — Principal investigator
First posted
Mar 18, 2026
Start date
Mar 4, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Alla A. Garganeeva, MD, PhD
Contact
aag@cardio-tomsk.ru
+7 (3822) 56 52 75
Elena A. Kuzheleva, MD, PhD
Contact
kea@cardio-tomsk.ru
+7 (3822) 56 52 75
Alla A. Garganeeva, MD, PhD
principal investigator · Tomsk NRMC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion